X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development FDA Approvals

Elsevier and FDA to work on AI algorithm for drug-induced liver injury

Content Team by Content Team
26th November 2019
in FDA Approvals, Press Statements
Elsevier and FDA to work on AI algorithm for drug-induced liver injury

Elsevier is working with the National Center for Toxicological Research (NCTR) at the FDA on a predictive drug-induced liver injury (DILI) algorithm. The company started the project by integrating the rule-of-two model and preclinical data from the literature and the summary basis of FDA and European Medicines Agency (EMA) approval documents collected in Elsevier’s PharmaPendium database.

DILI is one of the two most frequent causes for drug withdrawals and is a leading cause of attrition of compounds in drug development. More so, an analysis of over 500 withdrawals shows that DILI is the leading cause for toxicity-related drug withdrawals. In the United States DILI is also a leading reason for regulatory actions involving investigational and approved medications and a leading cause of acute liver failure.

A major problem in drug development is the frequency of adverse hepatic reactions induced by new molecular entities (NMEs). Mitigating DILI risk as early as possible during drug development can lower R&D costs and more importantly, improve patient safety, particularly in oncology.

Elsevier intends to use its algorithm to assess DILI in the preclinical phase of drug development and it could be utilised by the FDA when toxicology issues arise during different stages of the regulatory review process.

“The predictive toxicology space is becoming a growing area of interest as we seek to understand how to improve clinical outcomes without risking the safety of patients,” said Guenther Kurapkat, senior vice president, Life Science Solutions, Elsevier. “This (Collaborative Research and Development Agreement) CRADA will strengthen the collaborative relationship between Elsevier and the FDA and paves a path forward for future projects that seek to address key pain points for the industry, which continues to be challenged with rising R&D costs and low success rates.”

Previous Post

Aquestive Therapeutics Receives FDA Approval for Exservan Oral Film

Next Post

Dicerna, Novo Nordisk sign RNAi deal for liver-related cardio-metabolic diseases

Related Posts

FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Pharmapack 2023 a pivotal moment for sustainability in drug delivery and packaging
Europe

Pharmapack 2023 a pivotal moment for sustainability in drug delivery and packaging

3rd March 2023
Canada's National Carrier Air Canada Cargo and the Cool Tech Company ColdChase join Pharma.Aero
Manufacturing

Canada’s National Carrier Air Canada Cargo and the Cool Tech Company ColdChase join Pharma.Aero

22nd February 2023
Gavi, the Vaccine Alliance, Collaborates with Salesforce to Help Equitably Distribute Two Billion COVID-19 Vaccines by the End of 2021
FDA Approvals

WHO grants prequalification GC Biopharma’s varicella vaccine, Barycela

21st February 2023
Amyris and Immunitybio Complete Joint Venture for Next Generation Covid-19 RNA Vaccine
Drug Development

Clover Launches COVID-19 Booster Vaccine in the People’s Republic of China

21st February 2023
Labcorp Unveils New Name for Future Independent Clinical Development Business - Fortrea
Clinical Trials

Labcorp Unveils New Name for Future Independent Clinical Development Business – Fortrea

21st February 2023
Next Post
Dicerna, Novo Nordisk sign RNAi deal for liver-related cardio-metabolic diseases

Dicerna, Novo Nordisk sign RNAi deal for liver-related cardio-metabolic diseases

Latest News

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In